LMP Capital and Income Fund Inc. — News

Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term treatment adherence by Parkinson patients affected by dysphagia, an ODF formulation was developed demonstrating ~150% higher systemic bioavailability and ~300% significant increase in CNS exposure than conventional oral administration.

prnewswire.com - 2026-07-28 07:00:00

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 10% plus yield and nearly 7.7% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

seekingalpha.com - 2026-07-25 08:30:00

LMP Capital and Income Fund Inc. (NYSE: SCD - Get Free Report) shares crossed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $15.40 and traded as low as $15.35. LMP Capital and Income Fund shares last traded at $15.46, with a volume

defenseworld.net - 2026-07-22 03:42:23

Galmed has developed, in collaboration with Barcode Nanotech, a unique proprietary lipid nanoparticles (LPNs) novel formulation of Aramchol that penetrates the heart tissue and redirects Aramchol's biodistribution away from liver-hepatocytes to the heart's muscle. Cardiac fibrosis is a major driver of chronic heart failure, the leading cause of death globally, responsible for an estimated 20.5 million deaths in 2025.

prnewswire.com - 2026-07-16 07:30:00

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.8% plus yield and nearly 7.5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

seekingalpha.com - 2026-06-27 08:15:00

LMP Capital and Income Fund maintains a 9.2% yield, with management expressing confidence in sustaining current distributions through August. Recent performance and distribution consistency have been concerns, leading to a hold rating on SCD. Franklin Templeton's management strategy and risk profile are key considerations for SCD's forward outlook.

seekingalpha.com - 2026-06-18 02:42:46

[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVYÂ (exagamglogene autotemcel

gurufocus.com - 2026-06-11 03:00:00

The article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9% plus yield and nearly 7.5% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.

seekingalpha.com - 2026-05-23 08:30:00

Emmaus Life Sciences, Inc. (OTCQB: EMMA),a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its

gurufocus.com - 2026-05-15 16:00:00